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Abstract. Elevated plasma homocysteine is connected to atherosclerosis and increased cerebrovascular 
and ischemic heart disease especially in the patients with type 2 diabetes. Effects of metformin (10 μg 
mL−1), insulin (1 mUI mL−1), and their combination administration in condition of mild 
hyperhomocysteinemia (30 μmol dm−3) and hyperglycemia (12 mmol dm−3) on human aortic endothelial 
cells (HAEC) was investigated. HAEC were cultured 4 h in a medium with homocysteine (7 and 30 μmol 
dm−3) and glucose (5.5 and 12.0 mmol dm−3). E-selectin, intercellular adhesion molecule-1 (ICAM-1), and 
vascular adhesion molecule-1 (VCAM-1) expressions were analysed by flow-cytometry. Controls were 
CAMs expression on HAEC in medium with physiological concentration of homocysteine and glucose. 
HAEC, incubated additionally with 30 μmol dm−3 homocysteine, increased expression of ICAM-1 for 65 
% (p = 0.07) and decreased of E-selectin for 30 % (p = 0.07) and VCAM-1 for 13 % (0.06). In condition 
of mild hyperhomocysteinemia and hyperglycemia there was a statistically significant increase of ICAM-
1 expression (for 22 %, p = 0.04), while administration of metformin and insulin did not statistically sig-
nificantly influence adhesion molecules expression. Observed significant overexpression of ICAM-1, 
leads us to conclude that combination of mild hyperhomocisteinemia and hyperglycemia could have sig-
nificant influence on development of inflammation and atherosclerosis in diabetic patients.(doi: 
10.5562/cca1810) 
Keywords: Cell adhesion molecules, human aortic endothelial cells, mild hyperhomocysteinemia, mild 
hyperglycemia, metformin, insulin 
 
INTRODUCTION 
Homocysteine (Hcy) is sulfhydryl amino acid metabo-
lite of dietary methionine. Elevated plasma Hcy is one 
of independent cardiovascular risk factors. It is connect-
ed to accelerated atherosclerosis and increased cerebro-
vascular and ischemic heart disease.1 Further, more 
often Hcy levels are elevated modestly in the general 
population. These are strong predictors of existent and 
future development of vascular pathologies.2 
Magnified plasma level of Hcy seems to contrib-
ute to cardiovascular disease, in part, by inducing endo-
thelial cell (EC) dysfunction. In vivo, moderately ele-
vated Hcy causes EC damage and exacerbates hyperten-
sion-related atherosclerosis,3 and also impairs flow-
mediated arterial dilation.4 Additionally, elevated plas-
ma Hcy level is an independent predictor of coronary 
heart disease events in patients with type 2 diabetes 
mellitus.5 In vitro, Hcy increases leukocyte adhesion to 
cultured endothelial cells,6 and upregulates vascular cell 
adhesion molecule-1 expression in cultured HAEC and 
enhances monocyte adhesion.7 
One of the key initial events in the development of 
atherosclerosis is the adhesion of monocytes to endothe-
lial cells, with subsequent transmigration into the vascu-
lar intimae. Leukocyte and vascular cell adhesion mole-
cules (CAMs) such as selectins, integrins, E-selectin, 
vascular adhesion molecule-1 (VCAM-1), and intercel-
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lular adhesion molecule-1 (ICAM-1) play critical roles 
in the adhesion of monocytes to endothelial cells. The 
expression of E-selectin, VCAM-1 and ICAM-1 is rela-
tively low in normal vascular cells and it is upregulated 
in response to various stimuli.8,9 
Metformin (N1,N1 –dimethylbiguanide) is widely 
used for the treatment of type 2 diabetes mellitus, espe-
cially if this disease is accompanied by obesity and 
insulin resistance.10−13 However, its administration is 
related to decrease of all-cause and cardiovascular risk 
of mortality.14,15 Such improvement in cardiovascular 
outcomes of metformin administration appears not to be 
connected only to glycemic control, but also to specific 
vasculoprotective effects of this medicine.14,16,17 In addi-
tion to its glucose-lowering effects, metformin seems to 
exert beneficial effects on several cardiovascular risk 
factors. These risk factors include dyslipidemia, activi-
ties of plasminogen activator inhibitor 1, C-reactive 
protein, fibrinogen, and insulin resistance and hyperin-
sulinemia.10,13,18−20 A mechanism of its action in the 
vascular wall is still unclear. It has been reported that 
metformin inhibits monocyte adhesion on human endo-
thelial cells induced by advanced glycation end-
products (AGE), expression of endothelial cell adhesion 
molecules and monocyte differentiation into macro-
phages and foam cell formation.21 
Insulin is a powerful anabolic hormone widely used 
as an anti-diabetic drug for treatment of type 1 and type 2 
diabetes mellitus.22 An association of hyper-insulinemia 
with increased coronary events in several epidemiological 
studies has led to the hypothesis that insulin may be 
atherogenic.23,24 On the other hand, studies of Aljada et 
al. have shown that insulin increases endothelial NOS (e-
NOS) expression in HAEC, exerts an anti-inflammatory 
effect at the endothelial cell level by reducing the expres-
sion of intercellular adhesion molecule–1, monocyte 
chemoattractant protein–1 (MCP-1), and the pro-
inflammatory transcription factor, nuclear factor-κB.25,26 
Although many studies have shown a correlation 
between hyperhomocysteinemia, hyperglycemia and 
cardiovascular disease, it remains unclear whether drug 
controlled hyperhomocysteinemia and hyperglycemia 
could reduce incidence or progression of macrovascular 
diseases by diminishing expression of CAMs. There-
fore, the aim of this study was to investigate effects of 
elevated homocysteine and glucose concentration, as 
well as metformin and insulin treatment on the E-
selectin, ICAM-1, and VCAM-1 expression on human 




Human aortic endothelial cells – HAEC (Cascade 
BiologicsTM , San Diego, CA) were grown 4 h in Medi-
um 200 (Cascade BiologicsTM) with low serum growth 
supplement-LSGS (Cascade BiologicsTM), 0.1 ng mL−1 
tumor necrosis factor-alpha (TNF-α; Sigma, St. Louis, 
Missouri, USA), homocysteine (DL-Homocysteine, 
Sigma Biochemicals, Dreisenhoffen, Germany) in range 
of concentration (7 and 30 μmol dm−3), and glucose 
(Merck, Darmstadt, Germany) in a range of concentra-
tion (5.5 and 12.0 mmol dm−3). HAEC were cultivated 
at 37 °C and 5 % CO2 and passaged once or twice per 




Metformin (1, 1-dimethylbiguanide hydrochloride) was 
supplied by Sigma Biochemicals (Dreisenhofen, Germa-
ny). The drug was dissolved in a phosphate buffered 
saline (PBS) and stored at 4 °C as a stock solution (10 mg 
mL−1). HAEC cells were treated 4 hour with metformin at 
concentration of 10 μg mL−1 representing relevant thera-
peutic plasma concentration in diabetic patients. 
Insulin (Actrapid Penfil 100 UI/mL, 3.5 mg mL−1) 
was kindly supplied by Novo Nordisk A/S (Bagsvaerd, 
Denmark). Used concentration of 1 mUI mL−1 is in the 
range of therapeutic plasma concentrations in diabetic 
patients. 
The influence of metformin and insulin and their 
combinations on CAMs expression was analyzed in 
conditions of mild hyperglycemia (12 mmol dm−3) and 
mild hyperhomocysteinemia (30 μmol dm−3). Cells 
grown in corresponding glucose and homocysteine 
concentrations and in physiological glucose and 
homocysteine concentration (5.5 mmol dm−3 and 7 μmol 
dm−3, respectively) were used as controls. 
 
Measurement of Adhesion Molecules Expression by 
Flow-cytometry 
HAECs were incubated with appropriate experimental 
compounds for 4 hours, washed twice with PBS, and 
incubated with fluorescent label-marked monoclonal 
antibodies (R-phycoerythrin, R-PE, conjugated mouse 
anti-human monoclonal antibody) anti E-selectin, anti-
ICAM-1 and anti-VCAM-1 (B.D. Pharmigen, San Die-
go) for 20 min at 4 °C. Percentage of positive cells were 
analyzed on a flow-cytometer (FACSCalibur, BD), after 
washing with PBS. A software system CELLQuest was 
used for data acquisition and analysis. Minimum of 
5x103 cells were analyzed and results were expressed as 
a percentage of fluorescent cells for each marker. 
 
Statistical analysis 
Statistical analysis was performed by one-way analysis 
of variance (ANOVA) followed by the Student-
Newman-Keuls test. Differences were considered to be 
statistically significant at p < 0.05 when applied 
Kruskal-Wallis or Mann-Whitney test. Results are ex-
pressed as the mean ± SEM (standard error mean). 
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RESULTS 
The expression of adhesion molecules E-selectin, 
ICAM-1 and VCAM-1 on HAEC cultivated in medium 
with increased Hcy concentration (30 μmol dm−3) is 
shown in Figure 1. Mild hyperhomocysteinemia in-
creased the expression of ICAM-1 for 65.4 %, (p = 
0.07), while the expression of E-selectin, (for 30 %, p = 
0.07) and VCAM-1 (for 13 %, p = 0.06) was decreased in 
comparison to their expressions on the HAEC cells in 
control medium. 
Figure 1. The effect of mild hyperhomocysteinemia on the
expression of adhesion molecules: E-selectin (a), ICAM-1 (b)
and VCAM-1 (c) on HAEC. The expression of E-selectin,
ICAM-1 and VCAM-1 on HAEC grown for 4 hours in condi-
tion of  mild hyperhomocysteinemia (30 μmol dm−3) was
monitored by flow cytometry.  Homocysteine concentration of
7 μmol dm−3 was used as a control. Glucose concentration in
all experiments was 5.5 mmol dm−3. Data represent the
mean ± SEM (standard error mean) of three independent
experiments. 
Figure 2. Effect of mild hyperglycemia and mild 
hyperhomocysteinemia on expression of adhesion molecules 
E-selectin (a), ICAM-1 (b) and VCAM-1 (c) on HAEC. The 
expression of adhesion molecules was measured by flow-
cytometry upon 4 hours of incubation with homocysteine (30 
μmol dm−3) and glucose (12.0 mmol dm−3Homocysteine 
concentrations of 7 μmol dm−3 and glucose 5.5 mmol dm−3
were used as controls. Data represent the mean ± SEM (stand-
ard error mean) of three independent experiments. 
* p = 0.039, for homocysteine 7 μmol dm−3 and glucose 5.5 
mmol dm−3 vs. homocysteine 30 μmol dm−3 and glucose 12.0 
mmol dm−3 (Student-N-K test was used to elevate the differ-
ences in the control vs. mild hyperhomocysteinemia and mild
hyperglycemia group). 
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Effects of mild hyperglicemia (12 mmol dm−3) 
and mild hyperhomocysteinemia (30 μmol dm−3) on 
expression of adhesion molecules are shown in Figure 
2. The expression of ICAM-1 was statistically signifi-
cant increased for 22 % (p = 0.04), while the expression 
of E-selectin was reduced for 29.7 % (p = 0.32) and 
VCAM-1 was decreased by 69 % (p = 0.22) on HAEC 
incubated in this medium compared to expression in 
control medium. 
Metformin and insulin were added separately and 
as a combination into the medium with 12 mmol dm−3 
glucose (mild hyperglycemia) and 30 μmol dm−3 
homocysteine (mild hyperhomocysteinemia) (Figure 3). 
Flow-cytometry showed that addition of metformin (10 
μg mL−1) decreased E-selectin expression by 22 %, and 
that addition of insulin (1 mUI mL−1) decreases E-
selectin expression by 36 % (p = 0.08). Addition of 
metformin and insulin combination decreased E-selectin 
expression by 56 % (p = 0.06) Metformin and insulin 
had the similar effects on other two investigated adhe-
sion molecules. The expression of ICAM-1 and VCAM-
1 was decreased by addition of metformin (14 % and 27 
%, respectively), insulin (18 % and 39 %, respectively) 
and combination of metformin and insulin (23 % and 52 
%; p = 0.11, respectively). The greatest decrease of 
adhesion molecules expression (E-selectin by 56 %, 
ICAM-1 by 23 %, and VCAM-1 by 52 %) was noticed 
when metformin 10 μg mL−1 and insulin 1 mUI mL−1 
were used (Figure 3). 
 
DISCUSSION 
The role of homocysteine (Hcy) as an independent car-
diovascular risk factor has been recognised,2,27−29 but its 
role in pathogenesis is not completely clear. Numerous 
in vivo studies showed that hyperhomocysteinemia 
provokes endothelial dysfunction increased by oxidative 
stress30,31 and decreases discharge of NO causing in-
crease of vasodilatation.32−34 Furthermore, elevated Hcy 
in plasma is connected to increased lipid peroxidation 
and production of reactive oxygen species (ROS),35−37 
which testify its thrombogenic activity and eventually 
disorder in the coagulation system.38−41 Silverman et al. 
showed that elevated Hcy in culture of human aortic 
endothelial cells after 24 h of incubation increases ex-
pression of VCAM-1 and adhesion of monocytes to the 
endothelial cells surface. In addition, the function of 
endothelial cells depends on endothelial cyclooxygenase 
activity and elevated Hcy influencing activity of endo-
thelium-derived nitrogenous oxide and reactive oxygen 
species as well.7 High Hcy concentration stimulates 
proliferation and migration of smooth muscular cells 
and collagen synthesis with thickening of tunica intima 
and media.35,37,42−45 All of the above mentioned indicates 
that high concentration of plasma Hcy has both, 
atherogenic and thrombogenic effect. 
Our experiments showed that exposure of HAEC 
to slightly elevated Hcy concentration (30 μmol dm−3) 
for 4 hours resulting with increased ICAM-1 expression 
by 65 % (p = 0.07). In the same experimental condition 
expression of E-selectin and VCAM-1 was decreased in 
comparison to control (Figure 1). This could be ex-
plained by chronology of CAMs expression in adhesion 
cascade.46 E-selectin increases first, and subsequently 
ICAM-1 and VCAM-1 expression could be observed. 
Based on this fact, in different experimental systems 
shorter of longer time of exposure and expression of 
other molecules in adhesion cascade would be detect-
ed.46−48 Although statistically insignificant observed 
Figure 3. Effect of metformin (10 μg mL−1) and insulin
(1 mUI mL−1) administration and their combinations on ex-
pression of adhesion molecules E-selectin (a), ICAM-1 (b) and
VCAM-1 (c) on HAEC in conditions of  mild hyperglycemia
(12.0 mmol dm−3) and mild hyperhomocysteinemia (30 μmol
dm−3). The expression of adhesion molecules was measured
by flow-cytometry After 4 hours of incubation with metfor-
min, insulin and their combinations in mild hyperhomo-
cysteinemia and mild hyperglycemia,. Homocysteine concen-
trations of 30 μmol dm−3 and glucose 12.0 μmol dm−3 were
used as controls. Measured values of the expression in medi-
um control were taken as 100 %. Data represent the mean ±
SEM (standard error mean) of three independent experiments.
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result is physiologically very important since ICAM-1 
expression is involved in the firm adhesion of mono-
cytes to endothelium and beginning of inflammatory 
and atherogenic events. Besides, results of our study 
showed that short time exposure to mild elevated Hcy 
concentration and mild hyperglycemia caused modest 
but statistically significant (p = 0.039) increase of 
ICAM-1 expression. Although changes in expression of 
other molecules did not reach statistically significant 
levels those suggests that exposure of HAEC to differ-
ent risk factors activate endothelial cells. 
Slightly elevated level of plasma Hcy could be 
found in the general populations, which magnify risk for 
different cardiovascular diseases.2,49,50 A role of 
homocysteine in the development of cardiovascular 
diseases in hyperglycemia is not clear yet. There are 
very few data resulting from in vitro investigation, and 
so far there are no available data about effects of com-
bined interaction of hyperhomocysteinemia and hyper-
glycemia on expression of adhesion molecules in vitro. 
Our results (Figure 2) show that mild hyperglycemia 
and mild hyperhomocysteinemia after short-term HAEC 
stimulation (for 4 hours) lead to increased ICAM-1 
expression, while high concentrations of glucose alone, 
did not exert such effect.51 Since increased ICAM-1 
expression is early key event in atherogenesis, our re-
sults address the pro-inflammatory and pro-atherogenic 
effect of this combination. Furthermore, it is noted that 
atherosclerosis develops faster in patients, who have 
more than one risk factor, no matter how noticeable it 
is.52 It is also observed that macrovascular complica-
tions develop faster in type 2 diabetic patients if they 
have additional risk factors of atherosclerosis, for ex-
ample hypertriglyceridemia, hypertension, smoking, or 
more of them at the same time.52,53 Direct relationship 
between high Hcy values in plasma and risks for cardi-
ovascular diseases in type 2 diabetics was also de-
scribed.5 In addition, in vivo studies point to plasmatic 
Hcy increase as an independent cardiovascular risk 
factor connected to atherosclerosis and ischemic cardio-
vascular disease.27−29 Results of our study support in 
vivo investigations49 demonstrating that apparently 
healthy men who have risk factors of atherogenesis 
(age, smoking, diabetes, systolic pressure, family anam-
nesis of coronary disease, serum concentration of 
homocysteine and fibrinogen), have increased sICAM-1 
and therefore, sICAM-1 should be tested as a possible 
marker of pre-clinical atherosclerosis. 
In this study, the effects of two risk factors on en-
dothelial cell activation in controlled conditions are 
described for the first time. Observed changes on cellu-
lar level shed a light on clinically observed fact that 
development of atherosclerosis in patients with mild 
hyperglycemia and mild hyperhomocysteinemia is fast-
er than in patients with only one risk factor. The ques-
tion arises whether the usage of ordinary drug treat-
ments decreases the expression of adhesion molecules 
and what is the most efficient drug treatment in those 
conditions. So far, there are no published data about 
effect of metformin and insulin on the expression of 
adhesion molecules in conditions of mild hyperglycemia 
and mild hyperhomocysteinemia. 
Furthermore, we showed that addition of drug 
(metformin 10 μg mL−1, insulin 1 mUI mL−1, metformin 
10 μg mL−1 and insulin 1 mUI mL−1) in medium with 12 
mmol dm−3 glucose and 30 μmol dm−3 Hcy decreases 
the expression of all three tested adhesion molecules. 
The highest reduction of CAMs expression was ob-
served after treatment with combination of metformin 
(10 μg mL−1) and insulin (1 mUI mL−1). Observed effect 
approves this often used drug combination. In a contrast 
to previously observed decrease of E-selectin after insu-
lin administration in mild hyperglycemia,51 perceived 
decrease was not statistically significant. There is a 
question of prevention of macrovascular complications 
in those patients and the influence of the usage of new 
therapeutically approaches. 
Results of this investigation showed that the ad-
ministration of metformin, insulin and their combina-
tions do not significantly change the expression of adhe-
sion molecules in conditions of mild hyperglycemia and 
mild hyperhomocysteinemia. It could be possible that 
the use of tested drugs in those conditions, without regu-
lation of both risk factors glycemia and hyperhomo-
cysteinemia is not sufficient to prevent the development 
of macrovascular complications of diabetes. It should be 
investigated whether the use of acetylsalicylic acid, 
statins, folic acid or their combinations leads to the 
decrease of expression of adhesion molecules and deac-
tivation of endothelial cells in mentioned conditions. 
Perhaps, the solution for the prevention of macro-
vascular complications in the diabetic disease should be 
a search for new drug treatments, which among other 
things could decrease the activation of endothelial cells 
and have anti-inflammatory effect.54,55 Despite the pos-
sibilities of advanced medicine, special attention should 
be given to primary prevention of diabetes through 
balanced diet, physical activity, and weight reduction. 
 
CONCLUSION 
Mild homocysteine concentration (30 µmol dm−3) dur-
ing short time exposure (4 hours) resulted in increased 
expression of ICAM-1. This is the precondition for 
adhesion of monocytes on endothelial cells and begin-
ning of inflammatory and atherogenic process. 
Mild hyperglycemia and mild hyperhomocysteine-
mia significantly increased expression of ICAM-1, 
already after short-term stimulation (4 hours). Expres-
sion of E-selectin and VCAM-1 was decreased. The 
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results showed the importance of combined interaction 
of hyperglycemia and hyperhomo-cysteinemia on the 
expression of adhesion molecules, and on their pro-
inflammatory and pro-atherogenic effect. 
The addition of medicaments (metformin 10 μg 
mL−1, insulin 1 mUI mL−1, and combination of metfor-
min 10 μg mL−1 and insulin 1 mUI mL−1) in medium 
with mild hyperglycemia and mild hyperhomocysteine-
mia decreased the expression of all three adhesion mol-
ecules. The greatest decrease, although not statistically 
significant, occurred after the addition of metformin 10 
μg mL−1 and insulin 1 mUI mL−1, which supports this 
often used drug treatment. This therapeutic combination 
results in a modest decrease in expression of adhesion 
molecules on endothelial cells. However, due to the 
other risk factors that may not be affected, this therapy 
alone seems unlikely to be sufficient to prevent the 
development of macrovascular complications in diabetic 
patients. In vivo studies should be done to test whether 
observed moderate changes in adhesion molecules ex-
pression have physiological and pathophysiological 
significance in living organism. 
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